Metotreksat Ebewe 100 mg/ml koncentrat za raztopino za infundiranje Slovenja - Sloven - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

metotreksat ebewe 100 mg/ml koncentrat za raztopino za infundiranje

ebewe pharma - metotreksat - koncentrat za raztopino za infundiranje - metotreksat 100 mg / 1 ml - metotreksat

Metotreksat Ebewe 100 mg/ml koncentrat za raztopino za infundiranje Slovenja - Sloven - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

metotreksat ebewe 100 mg/ml koncentrat za raztopino za infundiranje

ebewe pharma - metotreksat - koncentrat za raztopino za infundiranje - metotreksat 100 mg / 1 ml - metotreksat

Trobalt Unjoni Ewropea - Sloven - EMA (European Medicines Agency)

trobalt

glaxo group limited  - retigabin - epilepsija - antiepileptics, - zdravilo trobalt je indicirano kot dodatno zdravljenje epileptičnih napadov z odpornimi proti drogam s sekundarno generalizacijo ali brez nje pri bolnikih, starih 18 let ali več, pri katerih so se druge primerne kombinacije zdravil izkazale za neustrezne ali niso bile tolerirane.

Exalief Unjoni Ewropea - Sloven - EMA (European Medicines Agency)

exalief

bial - portela ca, s.a. - eslikarbazepin acetat - epilepsija - antiepileptics, - zdravilo exalief je indicirano kot dodatno zdravljenje pri odraslih z epileptičnim napadom s sekundarno generalizacijo ali brez nje.

Briviact (in Italy: Nubriveo) Unjoni Ewropea - Sloven - EMA (European Medicines Agency)

briviact (in italy: nubriveo)

ucb pharma sa - brivaracetam - epilepsija - antiepileptics, - briviact je indiciran kot dodatna terapija pri zdravljenju napadov s parcialnim nastopom s sekundarno generalizacijo ali brez nje pri odraslih in mladostnikih, starih od 16 let, z epilepsijo.

Fycompa Unjoni Ewropea - Sloven - EMA (European Medicines Agency)

fycompa

eisai gmbh - perampanel - epilepsije, delno - antiepileptics, druge antiepileptics - zdravilo fycompa je indicirano za dodatno zdravljenje epileptičnih napadov z ali brez sekundarnih generaliziranih napadov pri odraslih in mladostnikih, starih od 12 let, z epilepsijo. fycompa je primerna za adjunctive zdravljenju primarne splošni tonik-clonic zasegov v izobraževanju odraslih in mladostnikov bolnikih od 12. leta starosti z idiopatsko splošnih epilepsijo.

Abecma Unjoni Ewropea - Sloven - EMA (European Medicines Agency)

abecma

bristol-myers squibb pharma eeig - idecabtagene vicleucel - multiple myeloma; neoplasms; cancer; neoplasms, plasma cell; hemostatic disorders; vascular diseases; cardiovascular diseases; paraproteinemias; blood protein disorders; hematologic diseases; hemic and lymphatic diseases; hemorrhagic disorders; infectious mononucleosis; lymphoproliferative disorders; immunoproliferative disorders; immune system diseases - antineoplastična sredstva - abecma is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti cd38 antibody and have demonstrated disease progression on the last therapy.

Breyanzi Unjoni Ewropea - Sloven - EMA (European Medicines Agency)

breyanzi

bristol-myers squibb pharma eeig - cd19-directed genetically modified autologous cell-based product consisting of purified cd8+ t-cells (cd8+ cells), cd19-directed genetically modified autologous cell-based product consisting of purified cd4+ t cells (cd4+ cells) - lymphoma, large b-cell, diffuse; lymphoma, follicular; mediastinal neoplasms - antineoplastična sredstva - breyanzi is indicated for the treatment of adult patients with diffuse large b-cell lymphoma (dlbcl), high grade b-cell lymphoma (hgbcl), primary mediastinal large b-cell lymphoma (pmbcl) and follicular lymphoma grade 3b (fl3b), who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy.

Talvey Unjoni Ewropea - Sloven - EMA (European Medicines Agency)

talvey

janssen-cilag international n.v. - talquetamab - multiple myeloma - antineoplastična sredstva - talvey is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least 3 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti cd38 antibody and have demonstrated disease progression on the last therapy.

Tepkinly Unjoni Ewropea - Sloven - EMA (European Medicines Agency)

tepkinly

abbvie deutschland gmbh & co. kg - epcoritamab - lymphoma, large b-cell, diffuse - antineoplastična sredstva - tepkinly as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl) after two or more lines of systemic therapy.